Novartis licenses small molecule treatment for a genetic ultra-rare disease

By Maggie Lynch

- Last updated on GMT

(Image: Getty/rawpixel)
(Image: Getty/rawpixel)

Related tags Small molecule Small molecule drugs Rare disease Novartis Genetic testing License

Novartis enters a licensing and development agreement with Pharming group for ultra-rare disease treatment for more than $20m.

Per the agreement, Pharming will collaborate to develop and commercialize Novartis’ CDZ173, a small molecule phosphoinositide 3-kinase delta inhibitor to treat patients with activated phosphoinositide 3-kinase delta syndrome (APDS).

The specialty pharmaceutical company focused on rare disease treatments, Pharming, will pay Novartis $20m upfront. The drugmaker is eligible to receive regulatory and commercial milestones and double-digit royalties on net sales as well.

Novartis has completed all preclinical and clinical work to date and will continue to run ongoing registration-enabling trial, as well as the current open-label extension study.

With this agreement, Pharming will work with Novartis to complete enrollment of the ongoing trial. Upon approval of the drug candidate, Pharming will commercialize CDZ173 through its existing commercial infrastructure in the US and EU.

Sijmen de Vries, CEO of Pharming stated, “This is a great example of solid science and deep disease understanding coming together to create a real and personalized treatment option for patients with no prospect of treatment.”

An immune deficiency caused by a mutation in the PIK3CD gene, ADPS can cause patients to suffer early cell death and have difficulty reacting to infections. ADPS is an ultra-rare disease with rates of 1-2 per million across the world.

The gene mutation in PIK3CD increases activity in the phosphoinositide 3-kinase delta inhibitor which is a promotor of activity in the immune system, therefore, the cells involved in immune response can fail to be differentiated properly in patients with ADPS.

Related news

Show more

Related products

show more

ODM and CDASH in CRF design

ODM and CDASH in CRF design

Formedix | 10-Mar-2023 | Technical / White Paper

The lesser-known Operational Data Model (ODM) standard is often overlooked as it's not required by any regulators. So, why should you be interested...

4 Warning Signs Your Research Site Is in Trouble

4 Warning Signs Your Research Site Is in Trouble

Elligo Health Research® | 10-Mar-2023 | Insight Guide

You want your clinical research practice to be a success for your business and your patients, but how can you tell if it’s in trouble? Read this article...

How Sponsors Reduce Chaos in Decentralized Trials

How Sponsors Reduce Chaos in Decentralized Trials

Florence Healthcare | 08-Mar-2023 | Insight Guide

89% of research sponsors currently use and expect to continue the use of decentralized technologies and methods, according to our state of the industry...

2023 State of Clinical Trial Technology Report

2023 State of Clinical Trial Technology Report

Florence Healthcare | 01-Mar-2023 | Insight Guide

Discover the trends shaping clinical trial technology in 2023, from Site Enablement to eISFs, integrations, and site-sponsor collaboration. This report...

Related suppliers

Follow us

Products

View more

Webinars